Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

456 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Publisher Correction: The asymmetry of antimatter in the proton.
Dove J, Kerns B, McClellan RE, Miyasaka S, Morton DH, Nagai K, Prasad S, Sanftl F, Scott MBC, Tadepalli AS, Aidala CA, Arrington J, Ayuso C, Barker CL, Brown CN, Chang WC, Chen A, Christian DC, Dannowitz BP, Daugherity M, Diefenthaler M, El Fassi L, Geesaman DF, Gilman R, Goto Y, Guo L, Guo R, Hague TJ, Holt RJ, Isenhower D, Kinney ER, Kitts N, Klein A, Kleinjan DW, Kudo Y, Leung C, Lin PJ, Liu K, Liu MX, Lorenzon W, Makins NCR, de Medeiros MM, McGaughey PL, Miyachi Y, Mooney I, Nakahara K, Nakano K, Nara S, Peng JC, Puckett AJ, Ramson BJ, Reimer PE, Rubin JG, Sawada S, Sawada T, Shibata TA, Su D, Teo M, Tice BG, Towell RS, Uemura S, Watson S, Wang SG, Wickes AB, Wu J, Xi Z, Ye Z. Dove J, et al. Among authors: teo m. Nature. 2022 Apr;604(7907):E26. doi: 10.1038/s41586-022-04707-z. Nature. 2022. PMID: 35396581 No abstract available.
The asymmetry of antimatter in the proton.
Dove J, Kerns B, McClellan RE, Miyasaka S, Morton DH, Nagai K, Prasad S, Sanftl F, Scott MBC, Tadepalli AS, Aidala CA, Arrington J, Ayuso C, Barker CL, Brown CN, Chang WC, Chen A, Christian DC, Dannowitz BP, Daugherity M, Diefenthaler M, El Fassi L, Geesaman DF, Gilman R, Goto Y, Guo L, Guo R, Hague TJ, Holt RJ, Isenhower D, Kinney ER, Kitts N, Klein A, Kleinjan DW, Kudo Y, Leung C, Lin PJ, Liu K, Liu MX, Lorenzon W, Makins NCR, de Medeiros MM, McGaughey PL, Miyachi Y, Mooney I, Nakahara K, Nakano K, Nara S, Peng JC, Puckett AJ, Ramson BJ, Reimer PE, Rubin JG, Sawada S, Sawada T, Shibata TA, Su D, Teo M, Tice BG, Towell RS, Uemura S, Watson S, Wang SG, Wickes AB, Wu J, Xi Z, Ye Z. Dove J, et al. Among authors: teo m. Nature. 2021 Feb;590(7847):561-565. doi: 10.1038/s41586-021-03282-z. Epub 2021 Feb 24. Nature. 2021. PMID: 33627814
Addressing barriers and identifying facilitators to support informed consent and recruitment in the Cavernous malformations A Randomised Effectiveness (CARE) pilot phase trial: insights from the integrated QuinteT recruitment intervention (QRI).
Wade J, Farrar N, Realpe AX, Donovan JL, Forsyth L, Harkness KA, Hutchinson PJA, Kitchen N, Lewis SC, Loan JJM, Stephen J, Al-Shahi Salman R; CARE pilot trial collaboration. Wade J, et al. EClinicalMedicine. 2024 Apr 18;71:102557. doi: 10.1016/j.eclinm.2024.102557. eCollection 2024 May. EClinicalMedicine. 2024. PMID: 38813441 Free PMC article.
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.
Parker CC, Clarke NW, Cook AD, Kynaston H, Catton CN, Cross WR, Petersen PM, Persad RA, Saad F, Bower LC, Logue J, Payne H, Forcat S, Goldstein C, Murphy C, Anderson J, Barkati M, Bottomley DM, Branagan J, Choudhury A, Chung PWM, Cogley L, Goh CL, Hoskin P, Khoo V, Malone SC, Masters L, Morris SL, Nabid A, Ong AD, Raman R, Tarver KL, Tree AC, Worlding J, Wylie JP, Zarkar AM, Parulekar WR, Parmar MKB, Sydes MR; RADICALS investigators. Parker CC, et al. Lancet. 2024 Jun 1;403(10442):2405-2415. doi: 10.1016/S0140-6736(24)00548-8. Epub 2024 May 16. Lancet. 2024. PMID: 38763154 Free article. Clinical Trial.
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial.
Parker CC, Kynaston H, Cook AD, Clarke NW, Catton CN, Cross WR, Petersen PM, Persad RA, Pugh CA, Saad F, Logue J, Payne H, Bower LC, Brawley C, Rauchenberger M, Barkati M, Bottomley DM, Brasso K, Chung HT, Chung PWM, Conroy R, Falconer A, Ford V, Goh CL, Heath CM, James ND, Kim-Sing C, Kodavatiganti R, Malone SC, Morris SL, Nabid A, Ong AD, Raman R, Rodda S, Wells P, Worlding J, Parulekar WR, Parmar MKB, Sydes MR; RADICALS investigators. Parker CC, et al. Lancet. 2024 Jun 1;403(10442):2416-2425. doi: 10.1016/S0140-6736(24)00549-X. Epub 2024 May 16. Lancet. 2024. PMID: 38763153 Free article. Clinical Trial.
Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder Cancer.
Lenis AT, Whiting K, Ravichandran V, Tallman JE, Alam SM, Chu CE, Jesus Escano M, Bochner E, Katims A, Reisz PA, Truong H, Clinton TN, Telis L, Dason S, McPherson V, Teo MY, Funt S, Aggen D, Goh AC, Donahue TF, Cha EK, Donat SM, Herr HW, Dalbagni G, Schultz N, Berger MF, Bajorin DF, Rosenberg JE, Bochner BH, Ostrovnaya I, Al-Ahmadie H, Solit DB, Iyer G, Pietzak EJ. Lenis AT, et al. Among authors: teo my. JCO Precis Oncol. 2024 Apr;8:e2300274. doi: 10.1200/PO.23.00274. JCO Precis Oncol. 2024. PMID: 38691813
456 results